0000721371-22-000049.txt : 20220722 0000721371-22-000049.hdr.sgml : 20220722 20220722163509 ACCESSION NUMBER: 0000721371-22-000049 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220718 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220722 DATE AS OF CHANGE: 20220722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CARDINAL HEALTH INC CENTRAL INDEX KEY: 0000721371 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 310958666 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11373 FILM NUMBER: 221100318 BUSINESS ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147573033 MAIL ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: CARDINAL DISTRIBUTION INC DATE OF NAME CHANGE: 19920703 8-K 1 cah-20220718.htm 8-K cah-20220718
0000721371false00007213712021-04-022021-04-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 18, 2022
 
Cardinal Health, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Ohio 1-11373 31-0958666
(State or Other Jurisdiction
of Incorporation)
 (Commission
File Number)
 (IRS Employer
Identification No.)
7000 Cardinal Place, Dublin, Ohio 43017
(Address of Principal Executive Offices) (Zip Code)
(614) 757-5000
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common shares (without par value)CAHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨





Item 8.01. Other Events.

In June 2019, Melissa Cohen, a purported shareholder of Cardinal Health, Inc. (the "Company"), filed an action on behalf of the Company in the U.S. District Court for the Southern District of Ohio against certain current and former members of the Company's Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor the Company's distribution of controlled substances and approving certain payments of executive compensation. In December 2019 and January 2020, similar complaints were filed in the U.S. District Court for the Southern District of Ohio by purported shareholders, Stanley M. Malone and Michael Splaine, respectively. In January 2020, the court consolidated these cases under the caption In re Cardinal Health, Inc. Derivative Litigation (the "Derivative Action"). In February 2021, the court dismissed the claim with respect to executive compensation but declined to dismiss the failure to monitor claim.

In December 2021, the parties reached an agreement in principle to resolve the Derivative Action ("Settlement") and in July 2022, the court granted preliminary approval of the Settlement. Subject to final approval by the court, as part of the Settlement, the Company's director and officer's liability insurance carriers, on behalf of the defendants, will pay the Company $124 million, less any attorneys' fees and expenses awarded by the court to plaintiffs' counsel. The Settlement does not include any admission of liability.

The Company today provided notice to its stockholders of the Settlement in the form of a press release as well as this Current Report on Form 8-K, as required by the terms of the Settlement. The terms and conditions of the Settlement are set forth in the Stipulation and Agreement of Compromise, Settlement, and Release (“Stipulation”) and the Notice to Cardinal Health, Inc. Stockholders of Proposed Settlement of Stockholder Derivative Action, Settlement Hearing, and Right to Appear (“Notice”).

Copies of the Stipulation and Notice are attached hereto as Exhibits 99.1 and 99.2 and are incorporated by reference herein. A copy of the news release issued by the Company is attached hereto as Exhibit 99.3.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits


2


Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Cardinal Health, Inc.
(Registrant)
Date:July 22, 2022By:/s/  JESSICA L. MAYER
Jessica L. Mayer
Chief Legal and Compliance Officer
3
EX-99.1 2 exhibit991-8xk.htm EX-99.1 Document
Exhibit 99.1
UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF OHIO
EASTERN DIVISION


IN RE CARDINAL HEALTH, INC.
DERIVATIVE LITIGATION


Case No. 2:19-cv-2491

Judge Sarah D. Morrison

Magistrate Judge Elizabeth A. Preston Deavers


STIPULATION AND AGREEMENT OF COMPROMISE, SETTLEMENT, AND RELEASE


This Stipulation and Agreement of Compromise, Settlement, and Release (the “Stipulation”) is entered into this 25th day of Mayl, 2022, by and among: (i) co-lead plaintiffs in the above-captioned stockholder derivative action Melissa Cohen, Stanley M. Malone, and Michael Splaine (collectively, “Plaintiffs”); (ii) individual defendants David J. Anderson, Colleen F. Arnold, George S. Barrett, Carrie S. Cox, Calvin Darden, Bruce L. Downey, Patricia A. Hemingway Hall, Akhil Johri, Clayton M. Jones, Michael C. Kaufmann, Gregory B. Kenny, Nancy Killefer, David P. King, and J. Michael Losh (collectively, “Individual Defendants”); and (iii) nominal defendant Cardinal Health, Inc. (“Cardinal Health” or the “Company,” and, together with the Individual Defendants, “Defendants”), constituting the parties (the “Parties” and, individually, a “Party”) in the above-captioned action (the “Action”), by and through their respective undersigned counsel.
This Stipulation is intended to fully, finally, and forever compromise, resolve, discharge, release, and settle the Released Claims (defined below) and dismiss the Action with prejudice, upon the terms and subject to the conditions set forth herein.
A.Opioid-Related Litigation and Settlements
WHEREAS, in October 2008, Cardinal Health entered into a settlement agreement with the U.S. Department of Justice, Drug Enforcement Administration (“DEA”) (the “2008 Settlement”), to settle administrative claims relating to the Company’s distribution of controlled substances;
WHEREAS, in connection with the 2008 Settlement, Cardinal Health agreed to, among other things, pay $34 million in settlement of claims or potential claims for civil penalties and maintain a compliance program designed to detect and prevent diversion of controlled substances as required under the Controlled Substances Act and applicable DEA regulations;
WHEREAS, in May 2012, Cardinal Health entered into a settlement with the DEA (the “2012 Settlement”) to resolve a DEA order initiating administrative proceedings to revoke the registration of a Cardinal Health distribution center in Lakeland, Florida (the “2012 Lakeland Order”);
WHEREAS, in connection with the 2012 Settlement, Cardinal Health did not then agree to pay a fine, but the government reserved its right to seek civil fines based on the conduct alleged in the 2012 Lakeland Order;



WHEREAS, in December 2016, Cardinal Health settled the government’s reserved claims for civil fines in connection with the 2012 Settlement and agreed to pay the United States $34 million;
WHEREAS, in December 2016, Kinray, LLC, a New York-based subsidiary of Cardinal Health, agreed to pay $10 million to settle a suit by the United States alleging that Kinray had failed to report suspicious orders placed by New York area pharmacies between January 1, 2011 and May 14, 2012;
WHEREAS, on December 12, 2017, the U.S. Judicial Panel on Multi-District Litigation centralized and transferred pending federal opioid-related cases brought by state and local governments against Cardinal Health, McKesson Corporation (“McKesson”), AmerisourceBergen Corporation (“AmerisourceBergen”), and certain pharmaceutical and pharmacy companies, to Judge Dan Polster in the United States District Court for the Northern District of Ohio (the “MDL”);
WHEREAS, in December 2019, Cardinal Health entered into a settlement agreement to resolve opioid-related claims by two Ohio counties, Summit and Cuyahoga;
WHEREAS, in July 2021, a bench trial involving certain of the cases in the MDL concluded in West Virginia, and the parties in that suit are awaiting a verdict;
WHEREAS, on July 21, 2021, Cardinal Health announced that it, McKesson, and AmerisourceBergen, had negotiated a proposed settlement agreement and settlement process that, if all conditions were satisfied, would result in the settlement of the vast majority of opioid lawsuits filed by state and local government entities (the “2021 Agreement”);
WHEREAS, the 2021 Agreement was binding as of February 25, 2022 and effective as of April 2, 2022, and includes injunctive relief terms governing the settling distributors’ controlled substance anti-diversion programs (the “Injunctive Relief Terms”), a copy of which is attached as Exhibit A, that have been or will be implemented on or before July 1, 2022;
B.This Action
WHEREAS, prior to the filing of the Consolidated Amended Complaint in the Action (the “Amended Complaint”) (ECF No. 35, PAGEID # 1715-1800), Plaintiffs obtained books and records from Cardinal Health pursuant to Section 1701.37 of the Ohio Revised Code;
WHEREAS, between June 14, 2019 and January 13, 2020, Plaintiffs filed three separate derivative actions (the “Individual Actions”) in this Court: (1) Melissa Cohen v. Arnold, et al., Case No. 2:19-cv-2491; (2) Stanley M. Malone v. Anderson, et al., Case No. 2:19-cv-5442; and (3) Michael Splaine v. Anderson, et al., Case No. 2:20-cv-203;
WHEREAS, on January 28, 2020, this Court entered an order consolidating the Individual Actions for all purposes into the Action, under the caption In re Cardinal Health, Inc. Derivative Litigation, Case No. 2:19-cv-2491;
WHEREAS, on February 11, 2020, the Court appointed Gardy & Notis, LLP and Kessler Topaz Meltzer & Check, LLP as co-lead counsel for Plaintiffs (“Co-Lead Counsel”), Isaac Wiles Burkholder & Teetor, LLC and Strauss Troy Co., LPA as co-liaison counsel for Plaintiffs, and Mark Troutman, Esq. as trial counsel for Plaintiffs in the Action, and on February 6, 2021, Troutman joined The Gibbs Law Group, LLP and remained as trial counsel for Plaintiffs in the Action;



WHEREAS, on March 12, 2020, Plaintiffs filed the Amended Complaint;
WHEREAS, on June 19, 2020, Defendants filed a motion to dismiss the Amended Complaint (the “Motion to Dismiss”);
WHEREAS, the Parties fully briefed the Motion to Dismiss, and, on January 21, 2021, the Court held a hearing on the Motion to Dismiss;
WHEREAS, on February 8, 2021, the Court issued an order granting in part and denying in part the Motion to Dismiss (ECF No. 58, PAGEID # 2218-2263): (i) dismissing Count II of the Amended Complaint alleging waste of corporate assets, and (ii) sustaining Count I of the Amended Complaint alleging that the Individual Defendants breached their fiduciary duties;
WHEREAS, on March 25, 2021, United States Magistrate Judge Elizabeth A. Preston Deavers entered a Preliminary Pretrial Order (ECF No. 66, PAGEID # 2284-86), which, among other things, set certain deadlines for fact and expert discovery and other proceedings;
WHEREAS, on March 26, 2021, Plaintiffs propounded their First Request for Production of Documents, to which the Individual Defendants and Cardinal Health each served responses and objections on June 10, 2021;
WHEREAS, on April 7, 2021, Defendants each filed answers to the Amended Complaint and asserted various defenses with respect to Plaintiffs’ claims, and the Individual Defendants further denied that any fiduciary breach took place;
WHEREAS, between April 30, 2021 and December 1, 2021, Cardinal Health produced to Plaintiffs more than 15 million pages of documents;
WHEREAS, on October 28, 2021, Plaintiffs propounded their First Set of Interrogatories on Cardinal Health, to which Cardinal Health served responses and objections on December 8, 2021;
WHEREAS, the Parties engaged in numerous meet-and-confer sessions regarding various discovery matters and also began a discussion regarding a potential resolution of the Action;
C.The Settlement
WHEREAS, on December 9, 2021, counsel for the Parties and representatives of Defendants’ directors and officers liability insurers (“D&O Insurers”), participated in a mediation session with the Hon. Daniel Weinstein (Ret.) and Jed D. Melnick, during which the Parties agreed in principle to settle the Action in return for a cash payment of one hundred twenty-four million dollars ($124,000,000), to be paid by the D&O Insurers (the “Settlement Amount”) to the Company;
WHEREAS, after the substantive terms of the Settlement were agreed to, the Parties separately negotiated in good faith as to an appropriate Fee and Expense Award (defined below), and Cardinal Health has agreed, subject to approval of the Court, that Plaintiffs’ Counsel (defined below) are entitled to a fee and expense award of 25% of the Settlement Amount for their role in prosecuting and settling the Action;
WHEREAS, this Stipulation (together with the exhibits hereto) reflects the final and binding agreement by and among the Parties;



WHEREAS, Plaintiffs continue to believe that their claims have merit but, based upon Plaintiffs’ and Co-Lead Counsel’s investigation and prosecution of the Action, Plaintiffs and Co-Lead Counsel have concluded that the terms and conditions of this Stipulation are fair, reasonable, and adequate to the Company and its stockholders;
WHEREAS, Plaintiffs have agreed to settle and release the claims asserted in the Action pursuant to the terms and provisions of this Stipulation, after considering (i) the substantial financial benefit under the Settlement; (ii) the comprehensive Injunctive Relief Terms already contemplated by the 2021 Agreement; (iii) the uncertain outcome, inherent delays, and significant risks of continued litigation; and (iv) the desirability of permitting the Settlement to be consummated as provided by the terms of this Stipulation;
WHEREAS, each of the Individual Defendants have denied, and continue to deny, that he or she committed, attempted to commit, or aided and abetted in the commission of, any breaches of fiduciary duty owed to Cardinal Health, or any violation of law or wrongdoing whatsoever, and expressly maintains that, at all relevant times, he or she acted in good faith and in a manner that he or she reasonably believed to be in the best interests of Cardinal Health and its stockholders;
WHEREAS, each of the Individual Defendants deny the allegations made by Plaintiffs in the Action and deny that Plaintiffs, Cardinal Health, or its stockholders suffered any damage or were harmed as a result of any act, omission, or conduct by the Individual Defendants as alleged in the Action;
WHEREAS, Cardinal Health believes that the Settlement is in the best interest of the Company, its stockholders, and its employees;
WHEREAS, Defendants are entering into this Settlement for the benefit of Cardinal Health to eliminate the uncertain outcome, distraction, disruption, burden, and expense inherent in further litigation;
WHEREAS, the Parties agree that this Stipulation (including the exhibits hereto) shall in no event be construed as, or deemed to be evidence of, an admission or concession by Defendants with respect to any claim of fault, liability, wrongdoing, or damage or any defect in the defenses that Individual Defendants have, or could have asserted; and
WHEREAS, the Parties recognize and acknowledge that (i) Plaintiffs initiated, filed, and prosecuted this Action in good faith, (ii) Defendants defended the Action in good faith, and (iii) the terms of the Settlement and this Stipulation are fair, reasonable, and adequate to the Company and its stockholders.
NOW, THEREFORE, IT IS HEREBY STIPULATED AND AGREED, by and among Plaintiffs (for themselves and derivatively on behalf of Cardinal Health), the Individual Defendants, and Cardinal Health, each by and through their respective undersigned counsel, that in exchange for the consideration set forth below and the benefits flowing to the Parties from the Settlement, and subject to the approval of the Court, the Action and the Released Claims (as defined below) shall be and hereby are fully, finally, and forever settled, compromised, discharged, relinquished, and released, and the Action shall be dismissed with prejudice as to all Defendants and claims, with full preclusive effect, as to all Parties, upon and subject to the terms and conditions of the Stipulation, as set forth below.



1.DEFINITIONS

In addition to the terms defined elsewhere in this Stipulation, the following capitalized terms, used in this Stipulation, shall have the meanings specified below:
1.1 “Action” means the above-captioned action, In re Cardinal Health, Inc. Derivative Litigation, Case No. 2:19-cv-2491, as set forth above.
1.2 “Business Day” means any day other than a day on which the Court is required to close.
1.3 “Cardinal Health” or the “Company” means Cardinal Health, Inc., as set forth above.
1.4 “Co-Lead Counsel” means the law firms of Kessler Topaz Meltzer & Check, LLP and Gardy & Notis, LLP.
1.5 “Current Company Stockholder” means any Person who owns Cardinal Health common stock, as of the close of trading on the date of this Stipulation.
1.6 “Court” means the United States District Court for the Southern District of Ohio.
1.7 “D&O Insurers” means Defendants’ directors and officers liability insurers, as set forth above.
1.8 “Effective Date” means the date by which all of the events and conditions specified in Section 5.1 have been met and have occurred.
1.9 “Fee and Expense Award” has the meaning ascribed to it in Section 4.1 below.
1.10 “Final” means the time when a Judgment that has not been reversed, vacated, or modified in any way is no longer subject to appellate review, either because of a disposition on appeal and conclusion of the appellate process (including potential writ proceedings) or because of passage of time for seeking appellate or writ review without action. More specifically, it is that situation when: (i) no appeal or petition for review by writ has been filed and the time has passed for any notice of appeal or writ petition to be timely filed from the Judgment; or (ii) if an appeal is taken, the court of appeal has either affirmed the Judgment or dismissed that appeal and the time for any reconsideration or further appellate review has passed; or (iii) a higher court has granted further appellate review and that court has either affirmed the underlying Judgment or affirmed the court of appeal’s decision affirming the Judgment or dismissing the appeal or writ proceeding, and the time for any reconsideration or further appellate review has passed. For purposes of this paragraph, an appeal or proceeding seeking subsequent judicial review pertaining solely to attorneys’ fees or expenses or service awards, including any Fee and Expense Award, shall not in any way delay or preclude the Judgment from becoming Final. Any reference to the “Finality” of the Judgment shall incorporate the definition of Final in this paragraph.
1.11 “Individual Defendants” means David J. Anderson, Colleen F. Arnold, George S. Barrett, Carrie S. Cox, Calvin Darden, Bruce L. Downey, Patricia A. Hemingway Hall, Akhil Johri, Clayton M. Jones, Michael C. Kaufmann, Gregory B. Kenny, Nancy Killefer, David P. King, and J. Michael Losh, as set forth above.



1.12 “Judgment” means the final order and judgment to be rendered by the Court, in all material respects substantially in the form attached as Exhibit B hereto.
1.13 “Notice” means the Notice of Pendency and Proposed Settlement of Stockholder Derivative Action, Settlement Hearing, and Right to Appear, substantially in the form attached as Exhibit C hereto.
1.14 “Parties” means Plaintiffs, Individual Defendants, and Cardinal Health, as set forth above. “Party” means, individually, any of the Parties, as set forth above.
1.15 “Person” means an individual, corporation, limited liability corporation, professional corporation, partnership, limited partnership, limited liability partnership, association, joint stock company, estate, legal representative, trust, unincorporated association, government or any political subdivision or agency thereof, or any other business or legal entity.
1.16 “Plaintiffs” means Melissa Cohen, Stanley M. Malone, and Michael Splaine, as set forth above.
1.17 “Plaintiffs’ Counsel” means the law firms of Gardy & Notis, LLP, Kessler Topaz Meltzer & Check, LLP, Strauss Troy Co., LPA, Isaac Wiles Burkholder & Teetor, LLC, and The Gibbs Law Group, LLP.
1.18 “Preliminary Approval Order” means the order to be entered by the Court, in all material respects substantially in the form attached as Exhibit D hereto, including, among other things, preliminarily approving the terms and conditions of the Settlement as set forth in this Stipulation, directing that notice be provided to Current Company Stockholders, and scheduling a Settlement Hearing to consider whether the Settlement, the proposed Fee and Expense Award, and service awards to Plaintiffs should be finally approved and whether the Judgment should be entered.
1.19 “Related Persons” means past or present family members, spouses, heirs, trusts, trustees, executors, estates, administrators, beneficiaries, distributees, foundations, agents, employees, fiduciaries, partners, partnerships, general or limited partners or partnerships, joint ventures, member firms, limited liability companies, corporations, parents, subsidiaries, divisions, affiliates, associated entities, stockholders, principals, officers, directors, managing directors, members, managing members, managing agents, representatives, predecessors, predecessors-in-interest, successors, successors-in-interest, assigns, financial or investment advisors, advisors, consultants, investment bankers, entities providing any fairness opinion, underwriters, brokers, dealers, lenders, commercial bankers, attorneys, personal or legal representatives, accountants, insurers, co-insurers, reinsurers, and associates.
1.20 “Released Claims” means, collectively, the Released Defendant Claims and the Released Plaintiff Claims.
1.21 “Released Defendant Claims” means any and all claims, rights, demands, obligations, controversies, debts, disputes, damages, losses, causes of action, issues, liabilities, and charges of any kind or nature whatsoever, whether in law or equity, including both known claims and Unknown Claims, suspected or unsuspected, accrued or unaccrued, fixed or contingent, liquidated or unliquidated, matured or unmatured, foreseen or unforeseen, whether arising under federal or state statutory or common law, or any other law, rule, or regulation, whether foreign or domestic, that



Defendants have or could have asserted against the Released Plaintiffs or their counsel, arising out of, relating to, based upon, or involving the institution, prosecution, or settlement of the claims asserted against the Individual Defendants; provided, however, that the Released Defendant Claims shall not include (1) any claims arising out of, based upon, or relating to the enforcement of the Settlement or this Stipulation, or (2) any claims by Defendants related to insurance coverage or the right to indemnification.
1.22 “Released Defendant Persons” means, collectively, each and all of the Individual Defendants and the Company, and their respective attorneys, and each and all of their respective Related Persons.
1.23 “Released Persons” means, collectively, the Released Defendant Persons and the Released Plaintiffs. “Released Person” means, individually, any of the Released Persons.
1.24 “Released Plaintiff Claims” means any and all claims, rights, demands, obligations, controversies, debts, disputes, damages, losses, causes of action, issues, liabilities, and charges of any kind or nature whatsoever, whether in law or equity, including both known claims and Unknown Claims, suspected or unsuspected, accrued or unaccrued, fixed or contingent, liquidated or unliquidated, matured or unmatured, foreseen or unforeseen, whether arising under federal or state statutory or common law, or any other law, rule, or regulation, whether foreign or domestic, that (i) were asserted in any of the complaints filed in the Action, or (ii) could have been, or could be, asserted by Cardinal Health directly, by Plaintiffs directly, or by Plaintiffs or any Cardinal Health stockholder derivatively on behalf of Cardinal Health, against the Released Defendant Persons in any court, tribunal, forum, or proceeding, concerning, arising from, relating to, based upon, or involving, in any way whatsoever, any of the facts, allegations, practices, events, claims, disclosures, non-disclosures, occurrences, representations, statements, matters, transactions, conduct, actions, failures to act, omissions, or circumstances that were alleged or referred to in any of the complaints filed in the Action or in the prosecution or settlement of the Action, including but not limited to any and all such claims that were, could have been, or could be asserted by Cardinal Health, Plaintiffs or any other Cardinal Health stockholder derivatively on behalf of Cardinal Health, concerning, arising from, or relating to Cardinal Health’s liabilities associated with settled, pending, or future litigation or claims of any nature concerning, arising from, or relating to the underlying facts, conduct, events, occurrences, transactions, or allegations set forth or referred to in any of the complaints, including the Amended Complaint, filed in the Action; provided, however, that the Released Plaintiff Claims shall not include any claims arising out of, based upon, or relating to the enforcement of the Settlement or this Stipulation. For the avoidance of doubt, the Released Plaintiff Claims do not cover, settle, or release any direct claims held by any current, former, or future Cardinal Health stockholder other than Plaintiffs, including any claims asserted under the federal or state securities laws.
1.25 “Released Plaintiffs” means each and all of the Plaintiffs and their respective attorneys, and each and all of their respective Related Persons.



1.26 “Settlement” means the settlement by and among the Parties on the terms and conditions set forth in this Stipulation.
1.27 “Settlement Amount” means one hundred twenty four million dollars ($124,000,000) in cash to be paid by Defendants’ D&O Insurers.
1.28 “Settlement Hearing” means the hearing to be held by the Court upon duly given notice to review this Stipulation and its exhibits, as well as the application for the Fee and Expense Award, and determine whether the Settlement should be finally approved, whether the Fee and Expense Award should be finally approved, whether service awards to Plaintiffs should be paid from any such award, and whether the Judgment should be entered.
1.29 “Summary Notice” means the Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Action, substantially in the form attached as Exhibit E hereto.
1.30 “Unknown Claims” means any Released Claims that any of the Parties or any Cardinal Health stockholder does not know or suspect to exist in his, her, or its favor at the time of the release of such claims, including claims which, if known by him, her, or it, might have affected his, her, or its decision to settle or the terms of his, her, or its settlement with and releases provided to the other Parties, or might have affected his, her, or its decision not to object to this Settlement. With respect to any and all Released Claims, the Parties stipulate and agree that, upon the Effective Date, the Parties shall expressly waive, and, with respect to Released Plaintiff Claims that could have been or could be asserted derivatively on behalf of the Company, all other Cardinal Health stockholders by operation of the Judgment shall have expressly waived, the provisions, rights, and benefits of California Civil Code § 1542, or any other law of the United States or any state or territory of the United States, or principle of common law or foreign law that is similar, comparable, or equivalent to Section 1542, which provides:
A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.

The Parties and each Cardinal Health stockholder may hereafter discover facts in addition to or different from those which he, she, or it now knows or believes to be true with respect to the subject matter of the Released Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed upon any theory of law or equity, but the Parties and each Cardinal Health stockholder derivatively on behalf of the Company shall expressly, fully, finally, and forever settle and release, and upon the Effective Date and by operation of the Judgment shall have settled and released, fully, finally, and forever, any and all Released Claims as applicable without regard to the subsequent discovery or existence of such different or additional facts. The Parties acknowledge, and the Cardinal Health stockholders shall be deemed by operation of the Judgment



to have acknowledged, that the foregoing waiver was separately bargained for and is a key element of the Settlement of which this release is a part.
2.SETTLEMENT CONSIDERATION

2.1 In consideration for the full and final release, settlement, and discharge of any and all Released Plaintiff Claims against the Released Defendant Persons and the dismissal with prejudice of the Action on the terms and conditions set forth in this Stipulation:
(a) Defendants shall cause their D&O Insurers to pay the Settlement Amount, less any Fee and Expense Award paid to Plaintiffs’ Counsel pursuant to Section 4.2, to the Company, by wire transfer or check at the option of the D&O Insurers, no later than twenty (20) Business Days after the later of (1) the Court’s order approving the Settlement and entering the Judgment pursuant to Section 5.1(a)-(b); and (2) receipt of payee information, check and/or wire instructions as applicable, and tax identification information for the payment from the Company; and
(b) to the extent the Settlement is terminated or cancelled pursuant to any of the conditions set forth in Section 5.2, the Company shall make a full refund to the D&O Insurers of the payment the Company received under Section 2.1(a), no later than twenty (20) Business Days after the Settlement has been so terminated or cancelled, and such refund will be distributed to the D&O Insurers in accordance with the provisions of separate funding agreements between Defendants and the D&O Insurers entered into in connection with the Settlement.
2.2 Defendants’ D&O Insurers’ payment of the Settlement Amount as provided in Sections 2.1(a) and 4.2 of this Stipulation shall constitute full and final satisfaction of all of the Released Plaintiff Claims. Defendants’ sole monetary obligation under the Settlement shall be to cause to be paid the Settlement Amount by their D&O Insurers as provided in this Stipulation, and they shall not be liable for any other amounts, including any Court-awarded attorneys’ fees and litigation expenses to Plaintiffs’ Counsel, which shall be paid, if awarded, out of the Settlement Amount.
3.SUBMISSION OF THE SETTLEMENT TO THE COURT FOR APPROVAL

3.1 As soon as practicable after this Stipulation has been executed, Plaintiffs’ Counsel shall submit this Stipulation, together with its exhibits, to the Court and file a motion for preliminary approval of the Settlement, requesting, among other things: (i) preliminary approval of the Settlement set forth in this Stipulation and entry of the Preliminary Approval Order substantially in the form attached as Exhibit D hereto; (ii) approval of the method of providing notice to Current Company Stockholders and approval of the forms of Notice and Summary Notice attached as Exhibits C and E hereto; and (iii) a date for the Settlement Hearing.
3.2 The proposed Preliminary Approval Order provides that, within ten (10) Business Days following the entry of a Preliminary Approval Order (the “Notice Date”), the Company shall: (i) file a Form 8-K with the SEC that includes the



Notice as an attachment; (ii) post this Stipulation and the Notice on the investor relations section of the Company’s website until the Effective Date of the Settlement; and (iii) issue a press release on PR Newswire or other equivalent national press release service that includes the Summary Notice. The proposed Preliminary Approval Order also provides that, within ten (10) Business Days of the Notice Date, the Company shall cause the Summary Notice to be published in The Wall Street Journal. The Company shall assume all administrative responsibility for and will pay any and all costs of notice of the Settlement by these methods, regardless of whether the Court approves the Settlement or the Effective Date fails to occur. Neither Plaintiffs nor Plaintiffs’ Counsel shall be responsible for any costs of notice of the Settlement, except that Co-Lead Counsel shall also make copies of the Notice and Summary Notice available on their respective websites, and shall bear the administrative responsibility for such posting and any costs thereof.
3.3 The Parties believe the content and manner of the Notice and Summary Notice, as set forth in Sections 3.1 and 3.2, constitutes adequate and reasonable notice pursuant to applicable law and due process.
3.4 The Parties agree to request that the Court hold a hearing in the Action no earlier than sixty (60) days after notice is given, at which time the Court will consider and determine whether the Judgment, substantially in the form of Exhibit B hereto, should be entered: (i) approving the terms of the Settlement as fair, reasonable, and adequate; (ii) dismissing with prejudice the Action; (iii) ruling upon Plaintiffs’ application for a Fee and Expense Award; and (iv) ruling upon Plaintiffs’ request for service awards.
3.5 Pending the Effective Date, the Parties agree that all proceedings and discovery in the Action shall be stayed (except as otherwise provided herein and in the proceedings necessary to effectuate the consummation and final approval of the Settlement) and not to initiate any other proceedings other than those related to the Settlement itself. The Parties shall not file, prosecute, instigate, or in any way participate in the commencement or prosecution of any of the Released Claims. The Parties shall cooperate to secure a postponement of any response deadline, hearing, or trial date(s) in the Action while this Settlement is under consideration by this Court.
4.FEE AND EXPENSE AWARD

4.1 In recognition of Plaintiffs’ Counsel’s role in prosecuting and settling the Action, Cardinal Health agrees that Co-Lead Counsel should receive a fee and expense award totaling 25% of the Settlement Amount, subject to Court approval (the “Fee and Expense Award”). Plaintiffs and Plaintiffs’ Counsel agree not to request any greater amount be awarded to Plaintiffs’ Counsel by the Court and not to seek the payment of attorneys’ fees and expenses from any person or entity other than Cardinal Health or Defendants’ D&O Insurers. Co-Lead Counsel also intend to seek Court approval of service awards for Plaintiffs of $2,500 each, which, if approved, will be paid out of the Fee and Expense Award.
4.2 The Parties acknowledge and agree that any Fee and Expense Award in connection with the Settlement shall be paid by Defendants’ D&O Insurers to Co-Lead Counsel, via wire transfer or check at the option of the D&O Insurers,



from the Settlement Amount, no later than twenty (20) Business Days after the later of (i) the date of entry of the Court’s order awarding such fees and expenses; and (ii) receipt of payee information, check and/or wire instructions as applicable, and tax identification information for the payment from Co-Lead Counsel. Any Fee and Expense Award shall be paid out of, and not be in addition to, the Settlement Amount.
4.3 The payment of any Fee and Expense Award to Co-Lead Counsel shall be subject to the joint and several obligation of Co-Lead Counsel to:
(a) in the event the Settlement is terminated or cancelled pursuant to Section 5.2, make full refund of any such payment to the D&O Insurers, which will be distributed to the D&O Insurers in accordance with instructions to be provided by the Individual Defendants’ counsel consistent with the provisions of separate funding agreements between Defendants and the D&O Insurers entered into in connection with the Settlement; and
(b) in the event the Fee and Expense Award is reduced or reversed as a result of any appeal or further proceedings on remand or successful collateral attack and such order reducing or reversing the award has become final, pay to Cardinal Health, in accordance with instructions to be provided by Cardinal Health’s counsel, the portion of any such reduction or reversal.
4.4 Co-Lead Counsel, in their sole discretion, shall be responsible for distributing the Fee and Expense Award among Plaintiffs’ Counsel. Any fees or expenses associated with Co-Lead Counsel’s distribution of the Fee and Expense Award shall be borne solely by Co-Lead Counsel. Defendants and their respective counsel shall have no responsibility for, and no liability whatsoever with respect to, the distribution or allocation of the Fee and Expense Award. Any dispute regarding the distribution or allocation of the Fee and Expense Award shall have no effect on the Settlement or the Releases.
4.5 Except as otherwise provided herein or except as provided pursuant to indemnification or insurance rights, each of the Parties shall bear his, her, or its own costs, expenses, and attorneys’ fees.
4.6 The amount of any Fee and Expense Award shall be subject to Court approval. The Court may consider and rule upon the fairness, reasonableness, and adequacy of the Settlement independently of the consideration of any Fee and Expense Award. Any changes by any court, including this Court, to the negotiated amount of any Fee and Expense Award, or to any service awards, will not otherwise affect the Finality of the Judgment or the validity of the Settlement, and the Parties’ obligations under the Settlement (except with respect to the payment of attorneys’ fees and expenses) shall not be conditioned on the resolution of, nor any ruling regarding, any Fee and Expense Award, including any service awards. Any orders or proceedings relating to any request for a Fee and Expense Award or service award, or any appeal from any order or proceedings relating thereto, shall not affect the validity of the



Settlement, operate to terminate or cancel the Stipulation, and/or affect or delay either the Effective Date or the Finality of the Judgment approving the Settlement.
5.CONDITIONS OF SETTLEMENT

5.1 The Effective Date of the Settlement shall be the date on which all of the following events have occurred:
(a) approval of the Settlement at or after the Settlement Hearing following notice to Current Company Stockholders as set forth in Section 3.2;
(b) entry of the Judgment, in all material respects in the form set forth as Exhibit B annexed hereto, approving the Settlement without the award of any damages, costs, or fees to any Party, except as provided for in this Stipulation; dismissing the Action with prejudice pursuant to the terms of this Stipulation; and releasing the Released Persons from the Released Claims; and
(c) the passing of the date upon which the Judgment, including dismissal of the Action with prejudice pursuant to the terms of this Stipulation, becomes Final.
5.2 If (i) the Court has refused to grant approval of the Settlement in any material respect, (ii) the Court alters the Judgment in any material respect prior to entry, or (iii) the Court enters the Judgment, but on or following appellate review, the Judgment is modified or reversed in any material respect, then this Stipulation and the Settlement shall be canceled and terminated, and the Judgment and any other order entered by the Court in accordance with the terms of this Stipulation and the Settlement shall be treated as vacated, nunc pro tunc, unless each of the Parties to this Stipulation, within ten (10) Business Days from receipt of such ruling, agrees in writing to proceed with the Settlement, including only with such modifications, if any, as to which all Parties agree; provided, however, that any such refusal, alteration, modification, or reversal with respect to any Fee and Expense Award or service award shall not be considered material to the Settlement, shall not affect the Finality of the Judgment, and shall not be grounds for cancelation or termination of this Stipulation and the Settlement.
5.3 If this Stipulation and the Settlement is canceled or terminated pursuant to Section 5.2 above, or fails to become Final in accordance with its terms or the Effective Date otherwise fails to occur, then: (i) the Settlement and the relevant portions of this Stipulation shall be canceled; (ii) Cardinal Health and Co-Lead Counsel shall comply with their repayment obligations set forth in Sections 2.1(b) and 4.3(a); (iii) the Parties shall be deemed to have reverted to their respective litigation status in the Action as of the date this Stipulation was executed; (iv) the terms and provisions of the Settlement and this Stipulation, with the exception of this Section 5.3, and Sections 2.1(b), 4.3(a), 7.1, 12.9, and 12.10, shall have no further force and effect with respect to the Parties and shall not be used in the Action or in any other proceeding for any purpose, and the Parties shall proceed in all respects as if the Settlement and this Stipulation had not been entered; and (v) the Judgment and any other order entered by the Court in accordance with the terms of this Stipulation shall be treated as vacated, nunc pro tunc.



6.DISMISSAL OF ACTION AND RELEASE OF CLAIMS

6.1 This Settlement is conditioned on the dismissal with prejudice of the Action at the time of final approval by the Court.
6.2 Plaintiffs shall provide reasonable documentary assistance to Defendants as requested to assist Defendants’ efforts to obtain dismissal of any stockholder derivative actions not listed above as part of the Action that may be later filed in any state or federal court asserting any of the Released Plaintiff Claims against the Released Defendant Persons.
6.3 Pursuant to the Judgment, without further action by anyone, upon the Effective Date, Cardinal Health acting directly, Plaintiffs acting directly on behalf of themselves and derivatively on behalf of Cardinal Health, and any other Cardinal Health stockholder acting derivatively on behalf of Cardinal Health, and any of their respective legal representatives, heirs, executors, administrators, predecessors, successors, predecessors-in-interest, successors-in-interest and assigns, shall be deemed to have, and by operation of the Judgment, shall have, fully, finally, and forever released, relinquished, settled, discharged, and dismissed with prejudice every one of the Released Plaintiff Claims (including Unknown Claims) against the Released Defendant Persons, and shall be forever barred and enjoined from asserting, commencing, instituting, prosecuting, or continuing to prosecute any of the Released Plaintiff Claims against any of the Released Defendant Persons.
6.4 Pursuant to the Judgment, without further action by anyone, upon the Effective Date, each of the Individual Defendants and Cardinal Health, and their respective legal representatives, heirs, executors, administrators, predecessors, successors, predecessors-in-interest, successors-in-interest and assigns, shall be deemed to have, and by operation of the Judgment, shall have, fully, finally, and forever released, relinquished, settled, discharged, and dismissed with prejudice every one of the Released Defendant Claims (including Unknown Claims) against the Released Plaintiffs, and shall be forever barred and enjoined from asserting any Released Defendant Claims against any of the Released Plaintiffs.
6.5 Nothing herein or in the Judgment shall in any way impair or restrict the rights of any Party to enforce the terms of this Stipulation, the Settlement, or the Judgment.
7.NO ADMISSION OF WRONGDOING

7.1 Neither this Stipulation (whether or not consummated), including the exhibits hereto, the negotiations leading to the execution of the Settlement, nor any proceedings taken pursuant to or in connection with the Settlement, this Stipulation, and/or approval of the Settlement (including any arguments proffered in connection therewith):
(a) shall be offered against any of the Released Defendant Persons as evidence of, or construed as, or deemed to be evidence of any presumption, concession, or admission by any of the Released Defendant Persons with respect to the truth of any fact alleged by Plaintiffs or the validity of any claim that was or could



have been asserted or the deficiency of any defense that has been or could have been asserted in the Action or in any other litigation, or of any liability, negligence, fault, or other wrongdoing of any kind of any of the Released Defendant Persons, or in any way referred to for any other reason as against any of the Released Defendant Persons, in any action or proceeding, other than such proceedings as may be necessary to effectuate the provisions of this Stipulation;
(b) shall be offered against any of the Released Plaintiffs as evidence of, or construed as, or deemed to be evidence of any presumption, concession, or admission by any of the Released Plaintiffs that any of the Released Plaintiff Claims are without merit, that any of the Released Defendant Persons had meritorious defenses, or that damages recoverable under the Amended Complaint would not have exceeded the Settlement Amount, or with respect to any liability, negligence, fault, or wrongdoing of any kind, or in any way referred to for any other reason as against any of the Released Plaintiffs, in any action or proceeding, other than such proceedings as may be necessary to effectuate the provisions of this Stipulation; or
(c) shall be construed against any of the Released Persons as an admission, concession, or presumption that the consideration to be given hereunder represents the amount which could be or would have been recovered after trial; provided, however, that if this Stipulation is approved by the Court, the Parties, the Released Persons, and their respective counsel, may refer to the Stipulation (including the exhibits thereto) to effectuate the protections from liability granted hereunder or otherwise to enforce the terms of the Settlement.
8.NO WAIVER

8.1 Any failure by any Party to this Stipulation to insist upon the strict performance by any other Party to this Stipulation of any of the provisions of this Stipulation shall not be deemed a waiver of any of the provisions hereof, and such Party, notwithstanding such failure, shall have the right thereafter to insist upon the strict performance of any and all of the provisions of this Stipulation to be performed by such other Party.
8.2 No waiver, express or implied, by any party to this Stipulation of any breach or default by any other Party to this Stipulation in the performance by the other Party of its obligations under this Stipulation shall be deemed or construed to be a waiver of any other breach, whether prior, subsequent, or contemporaneous, under this Stipulation.
9.RETENTION OF JURISDICTION AND PREVAILING PARTY

9.1 The Court shall retain exclusive jurisdiction with respect to the interpretation, implementation, and enforcement of the terms of this Stipulation, and the Parties and their undersigned counsel submit to the jurisdiction of the Court for purposes of implementing and enforcement of the Settlement embodied in this Stipulation.



In any action brought to enforce the terms of this Stipulation and the Settlement contemplated by it, the party prevailing on any claim, matter, or issue shall be entitled to recover from the losing party all reasonable fees, expenses, and costs, including, but not limited to, attorneys’ fees, incurred in bringing such claim, matter, or issue.
10.RIGHT TO INJUNCTIVE RELIEF

10.1 The Parties acknowledge and agree that (i) any breach of this Stipulation may result in immediate and irreparable injury for which there is no adequate remedy available at law and (ii) in addition to any other remedies available, specific performance and injunctive relief are appropriate remedies to compel performance of this Stipulation.
11.SUCCESSORS AND ASSIGNS

11.1 This Stipulation is and shall be binding upon, and shall inure to the benefit of, the Parties (and, in the case of the releases, all Released Persons as third-party beneficiaries) and their respective legal representatives, heirs, executors, administrators, predecessors, successors, predecessors-in-interest, successors-in-interest, and assigns of any of the foregoing, including, but not limited to, any corporation or other entity with which any party hereto may merge, reorganize or otherwise consolidate.
12.MISCELLANEOUS

12.1 The Parties (i) acknowledge that it is their intent to consummate the Settlement; and (ii) agree to act in good faith and cooperate fully with one another to take all reasonable and necessary steps to expeditiously implement the terms and conditions of the Settlement set forth in this Stipulation. The Parties agree to use their reasonable best efforts to obtain the Court’s approval of this Stipulation and the Settlement and a dismissal with prejudice of the Action (including, but not limited to, resolving any objections raised to the Settlement). The Parties represent and agree that the terms of this Stipulation and the Settlement were negotiated at arm’s-length and in good faith, and reflect a settlement that was reached voluntarily based upon adequate information and sufficient discovery and after consultation with experienced legal counsel.
12.2 All of the exhibits attached hereto are material and integral parts hereof and shall be incorporated by reference as though fully set forth herein. Notwithstanding the foregoing, in the event that there exists a conflict or inconsistency between the terms of this Stipulation and the terms of any exhibit attached hereto, the terms of the Stipulation shall prevail.
12.3 This Stipulation and the exhibits hereto constitute the entire agreement among the Parties with respect to the Settlement and this Stipulation and its exhibits, and supersede any and all prior negotiations, discussions, agreements, or undertakings with respect to such matters, and may not be amended or modified, nor may any of its provisions be waived, except by a writing signed by or on behalf of all of the Parties hereto or their successors-in-interest. All Parties acknowledge that, in entering into this Stipulation and Settlement, they are not relying upon any statements, agreements, representations, warranties, or inducements by any Party except as expressly set forth in this Stipulation.



12.4 Plaintiffs represent and warrant that they have not assigned or transferred or attempted to assign or transfer, to any Person any Released Plaintiff Claims or any portion thereof or interest therein.
12.5 The headings herein are used for the purpose of convenience only and are not meant to have legal effect.
12.6 The Stipulation and the exhibits attached hereto shall be considered to have been negotiated, executed, and delivered, and to be wholly performed, in the State of Ohio, and the rights and obligations of the Parties to the Stipulation shall be construed and enforced in accordance with, and governed by, the internal, substantive laws of Ohio without giving effect to that State’s choice-of-law principles.
12.7 This Stipulation may be executed in one or more counterparts, each of which so executed shall be deemed to be an original and such counterparts together constitute one and the same Stipulation. The Parties agree that signatures submitted through facsimile or by e-mailing .PDF files or signed using DocuSign shall constitute original and valid signatures.
12.8 Without further order of the Court, the Parties may agree to reasonable extensions of time to carry out the provisions of this Stipulation through written agreement signed by counsel for all Parties.
12.9 To the extent permitted by law, all designations and agreements made and orders entered during the course of or in the Action relating to the confidentiality of documents or information shall survive this Stipulation and the Settlement, and any termination thereof. Nothing in this Stipulation, or the negotiations relating thereto, is intended to or shall be deemed to constitute a waiver of any applicable privilege, including, without limitation, the attorney-client privilege, the joint defense privilege, or work product protection.
12.10 Whether or not the Stipulation and the Settlement is approved by the Court and whether or not the Stipulation and the Settlement is consummated, or the Effective Date occurs, the Parties and their counsel shall use their reasonable best efforts to keep all negotiations, discussions, and drafts in connection with the Stipulation and the Settlement confidential.
12.11 This Stipulation shall be treated as jointly drafted and will not be construed against any Party as the drafter.
12.12 All counsel and any other person executing this Stipulation and any of the exhibits hereto, or any related Settlement documents, warrant and represent that they have the full authority to do so and that they have the authority to take appropriate action required or permitted to be taken pursuant to the Stipulation to effectuate its terms.
12.13 Any Party may give notice or service to another Party under this Stipulation. Such notice shall be in writing and shall be deemed to have been duly given upon receipt of hand delivery or email transmission, with confirmation of receipt. Notice shall be provided as follows:



For Plaintiffs:Justin O. Reliford
KESSLER TOPAZ MELTZER & CHECK, LLP
280 King of Prussia Road
Radnor, PA 19087
jreliford@ktmc.com

Jennifer Sarnelli
GARDY & NOTIS, LLP
156 East 56th Street, 8th Floor
New York, NY 10022
jsarnelli@gardylaw.com
For Individual Defendants:Robert W. Trafford
Porter Wright Morris & Arthur LLP
41 South High Street
Suites 2800 - 3200
Columbus, OH 43215
rtrafford@porterwright.com

William Savitt
Wachtell, Lipton, Rosen & Katz
51 West 52nd Street
New York, NY 10019
WDSavitt@wlrk.com
For Cardinal Health:Albert G. Lin
Baker Hostetler
200 Civic Center Drive, Suite 1200
Columbus, OH 43215
alin@bakerlaw.com

IN WITNESS WHEREOF, the Parties hereto have caused this Stipulation to be executed, by their duly authorized attorneys, as of May 25th, 2022.
KESSLER TOPAZ MELTZER & CHECK, LLP

____________________________
Lee Rudy
Eric L. Zagar
Justin O. Reliford
280 King of Prussia Road
Radnor, PA 19087
Phone: (610) 667-7706
Fax: (610) 667-7056
Email: lrudy@ktmc.com
Email: ezagar@ktmc.com
Email: jreliford@ktmc.com

Co-Lead Counsel Plaintiffs




GARDY & NOTIS, LLP

____________________________
James S. Notis
Jennifer Sarnelli
Meagan Farmer
126 East 56th Street, 8th Floor
New York, NY 10022
Phone: (212) 905-0509
Fax: (212) 905-0508
Email: jnotis@gardylaw.com
Email: jsarnelli@gardylaw.com
Email: mfarmer@gardylaw.com

Co-Lead Counsel Plaintiffs

THE GIBBS LAW GROUP, LLP

____________________________
Mark H. Troutman (0076390),
Trial Attorney*
Shawn K. Judge (0069493)*
505 14th Street, Suite 1110
Oakland, CA 94612
Phone: (510) 350-9700
Email: mht@classlawgroup.com
Email: sklj@classlawgroup.com
*Working from Ohio offices

Trial Counsel for Plaintiffs

STRAUSS TROY CO., LPA

____________________________
Richard S. Wayne (0022390)
William K. Flynn (0029536)
Robert R. Sparks (0073573)
150 E. Fourth Street
Cincinnati, OH 45202-4018
Phone: (513) 621-2120
Fax: (513) 629-9426
Email: rswayne@strausstroy.com
Email: wkflynn@strausstroy.com
Email: rrsparks@strausstroy.com




Liaison Counsel for Plaintiffs

WACHTELL LIPTON ROSEN & KATZ

____________________________
William Savitt
Lauren M. Kofke
Alexandra P. Sadinsky
51 West 52nd Street
New York, NY 10019
Phone: (212) 403-1000
Fax: (212) 403-2000
Email: wdsavitt@wlrk.com
Email: lmkofke@wlrk.com
Email: apsadinsky@wlrk.com

Counsel for the Individual Defendants

PORTER, WRIGHT, MORRIS & ARTHUR LLP

____________________________
Robert W. Trafford (0024447)
Trial Attorney
David S. Bloomfield, Jr. (0068158)
41 South High Street, Suite 2800
Columbus, OH 43215
Phone: (614) 227-2000
Fax: (614) 227-2100
Email: rtrafford@porterwright.com
Email: dbloomfield@porterwright.com

Counsel for the Individual Defendants

BAKER & HOSTETLER LLP

____________________________
Albert G. Lin (0076888)
Trial Attorney
Trischa Snyder Chapman (0086420)
Marissa A. Peirsol (0098203)
Erika Dackin Prouty (0095821)
200 Civic Center Drive, Suite 1200
Columbus, OH 43215
Phone: (614) 228-1541
Fax: (614) 462-2616
Email: alin@bakerlaw.com
Email: tchapman@bakerlaw.com
Email: mpeirsol@bakerlaw.com
Email: eprouty@bakerlaw.com

Counsel for Nominal Defendant


EX-99.2 3 exhibit992-8xk.htm EX-99.2 Document
Exhibit 99.2
Notice to Cardinal Health, Inc. Stockholders of Proposed Settlement of Stockholder Derivative Action, Settlement Hearing, and Right to Appear

The United States District Court for the Southern District of Ohio authorized this Notice

Please read this notice (the “Notice”) carefully and in its entirety. This Notice relates to a proposed settlement (the “Settlement”)1 of a consolidated stockholder derivative action (the “Action”) brought on behalf of Cardinal Health, Inc. (“Cardinal Health” or the “Company”) and pending in the United States District Court for the Southern District of Ohio, Eastern Division (the “Court”).

This Notice contains important information. Your rights will be affected by these legal proceedings. If the Court approves the Settlement, you will be forever barred from contesting the fairness, reasonableness, and adequacy of the Settlement and related matters, and from pursuing the Released Claims (as defined herein).

If the Settlement is approved by the Court, Cardinal Health will receive a $124 million cash payment, less any payments and expenses as described below. Please note that the Action is a derivative action where the legal claims were brought by Cardinal Health stockholders derivatively on behalf of, and for the benefit of, Cardinal Health itself. As a result, the Settlement provides that the cash recovery will be paid directly to Cardinal Health. You will not receive any direct payment, and do not need to submit any claim form in connection with the Settlement.

Why this Notice?

You have a right to know about the Settlement of the Action, and about all of your options, before the Court decides whether to approve the Settlement.

This Notice summarizes the Action, the Settlement, and your legal rights.

The Court in charge of the Action is the United States District Court for the Southern District of Ohio, Eastern Division, and the case is called In re Cardinal Health, Inc. Derivative Litigation, Case No. 2:19-cv-2491. The judge presiding over the Action is Judge Sarah D. Morrison. The stockholders who brought the Action are called the Plaintiffs,2 and the people who the stockholders have sued are called the Individual Defendants.3 The Action is a derivative action, which means that the Plaintiffs seek to pursue legal claims on behalf of, and for the benefit of, Cardinal Health itself and not any stockholders directly. Cardinal Health is named in the Action as a “Nominal Defendant” only, and there are no claims asserted against Cardinal Health. This Notice refers to Individual Defendants and Nominal Defendant collectively as the “Defendants,” and Plaintiffs and Defendants collectively as the “Parties.”

The Court will hold a hearing (the “Settlement Hearing”) to decide if the Settlement is fair and reasonable. If the Court approves the Settlement and the Settlement becomes effective, the Action will be dismissed with prejudice. If you were a stockholder of Cardinal Health as of the close of trading on the date of the Stipulation (May 25, 2022) and you continue to own such stock through the date of the Settlement Hearing, you have the right to tell the Court your opinion about the Settlement. Please see below for more details about how and when to file your opinion with the Court, if you so choose.

What is this Action about?

The following recitation does not constitute findings of the Court and should not be understood as an expression of any opinion of the Court as to the merits of any claims or defenses by any of the Parties.
1 All capitalized terms used in this Notice that are not otherwise defined herein shall have the meanings provided in the Stipulation and Agreement of Compromise, Settlement, and Release, dated May 25, 2022 (the “Stipulation”).
2 Plaintiffs are Melissa Cohen, Stanley M. Malone, and Michael Splaine. “Plaintiffs’ Counsel” consist of Gardy & Notis, LLP and Kessler Topaz Meltzer & Check, LLP, together acting as Co-Lead Counsel, and Isaac Wiles Burkholder & Teetor, LLC, Gibbs Law Group, LLP, and Strauss Troy Co., LPA.
3 Individual Defendants are current and former members of Cardinal Health’s Board of Directors: David J. Anderson, Colleen F. Arnold, George S. Barrett, Carrie S. Cox, Calvin Darden, Bruce L. Downey, Patricia A. Hemingway Hall, Akhil Johri, Clayton M. Jones, Michael C. Kaufmann, Gregory B. Kenny, Nancy Killefer, David P. King, and J. Michael Losh (collectively, “Individual Defendants”).




Between June 14, 2019 and January 13, 2020, Plaintiffs filed three separate actions that the Court consolidated into the Action on January 28, 2020. Plaintiffs obtained confidential internal documents from Cardinal Health as permitted under Ohio law and, on March 12, 2020, filed an amended complaint (the “Amended Complaint”), which is the operative complaint in the Action. The Amended Complaint alleged that the Individual Defendants breached their fiduciary duties under Ohio law by allegedly failing to properly oversee the Company’s compliance with controlled substances regulations and by allegedly approving improper compensation and bonuses to Company executives who allegedly failed to ensure compliance with such regulations.

Defendants asked the Court to dismiss the Action, and Plaintiffs opposed the request. Defendants and Plaintiffs presented arguments to the Court. On February 8, 2021, the Court dismissed the compensation-related claim, but declined to dismiss the oversight claim related to the Company’s compliance with controlled substances regulations. The Court did not make, and has not made, any final decisions about the merits of the surviving claim.

After the Court’s ruling, Plaintiffs continued to investigate their claims and obtain additional discovery. Between April 30, 2021 and December 1, 2021, Cardinal Health produced to Plaintiffs more than 15 million pages of documents, including deposition transcripts and written discovery responses from the “MDL” proceedings.4 Defendants also provided written responses to Plaintiffs’ discovery demands in the Action.

The Parties engaged the Hon. Daniel Weinstein (Ret.) and Jed D. Melnick, Esq. to act as private mediators to assist the Parties in negotiating a potential resolution. On December 9, 2021, counsel for the Parties and representatives of Defendants’ directors and officers liability insurers (“D&O Insurers”) participated in a mediation session, during which the Parties agreed in principle to settle the Action in return for a cash payment of one hundred twenty-four million dollars ($124,000,000), to be paid by the D&O Insurers to the Company.

The Settlement also provides that any fees and expenses to Plaintiffs’ Counsel would be paid exclusively from the $124 million Settlement amount. As those costs would reduce the net payment received by Cardinal Health, after the substantive terms of the Settlement were negotiated and agreed to, the Parties separately negotiated in good faith as to an appropriate amount of attorneys’ fees and expenses that Cardinal Health agreed was appropriate for Plaintiffs’ Counsel’s role in prosecuting the Action.
Following those negotiations, Cardinal Health has agreed, subject to approval of the Court, that Plaintiffs’ Counsel are entitled to a fee and expense award of 25% of the Settlement amount (the “Fee and Expense Award”).
The full terms and conditions of the Settlement, the Fee and Expense Award, and related matters are embodied in the Stipulation.

On July 18, 2022, the Court preliminarily approved the Settlement, authorizing this Notice and scheduling the Settlement Hearing to consider whether to grant final approval of the Settlement, the Fee and Expense Award, and related matters (the “Preliminary Approval Order”).

Why is there a Settlement and what are the terms?

Plaintiffs and Plaintiffs’ Counsel believe that the claims raised in the Action have merit and that their investigation supports the claims asserted. Without conceding the merit of any of Defendants’ defenses, and in light of the benefits of the Settlement as well as to avoid the potentially protracted time, expense, and uncertainty associated with continued litigation, including potential trial and appeal(s), Plaintiffs and Plaintiffs’ Counsel have concluded that it is desirable that the Action be fully and finally settled in the manner and upon the terms and conditions set forth in the Stipulation. Plaintiffs and Plaintiffs’ Counsel recognize the significant risk, expense, and length of continued proceedings necessary to prosecute the Action against Defendants through trial and through possible appeal(s). Plaintiffs’ Counsel have also taken into account the uncertain outcome and the risk of any litigation, especially complex litigation such as would be entailed by the Action, the difficulties and delays inherent in such
4 The “MDL” refers to consolidated proceedings of cases filed by state and local governments, tribal sovereign nations and others against various defendants, including Cardinal Health, that the U.S. Judicial Panel on Multi-District Litigation centralized and transferred into a multi-district litigation called In re National Prescription Opiate Litigation, Case No. MDL 2804 in the United States District Court for the Northern District of Ohio in December 2017. On July 21, 2021, Cardinal Health announced that it, McKesson Corporation (“McKesson”), and AmerisourceBergen Corporation (“AmerisourceBergen”), had entered into a settlement to resolve the vast majority of opioid lawsuits filed by state and local government entities. That settlement was binding as of February 25, 2022 and effective as of April 2, 2022, and includes injunctive relief terms relating to the settling distributors’ controlled substance anti-diversion programs that have been implemented on or before July 1, 2022.



litigation, the cost to Cardinal Health – on behalf of which Plaintiffs filed the Action – and distraction to management of Cardinal Health that would result from extended litigation. Based on their evaluation, and in light of what Plaintiffs and Plaintiffs’ Counsel believe to be the significant benefits conferred upon Cardinal Health as a result of the Settlement, Plaintiffs and Plaintiffs’ Counsel have determined that the Settlement is in the best interests of Plaintiffs, Cardinal Health, and Cardinal Health’s stockholders, and have agreed to settle the Action upon the terms and subject to the conditions set forth in the Stipulation.

Each of the Individual Defendants denied and continues to deny that he or she has committed or attempted to commit any violations of law, any breaches of fiduciary duty, or any wrongdoing whatsoever, and expressly maintains that, at all relevant times, he or she acted in good faith and in a manner that he or she reasonably believed to be in the best interests of Cardinal Health and its stockholders. Each of the Individual Defendants likewise denies all of the allegations made by Plaintiffs in the Action. The Individual Defendants further deny that Plaintiffs, Cardinal Health, or Cardinal Health’s stockholders suffered any damage or were harmed as a result of any act, omission, or conduct by the Individual Defendants as alleged in the Action or otherwise.

Cardinal Health believes that the Settlement is in the best interest of the Company, its stockholders, and its employees. Defendants are, therefore, entering into this Settlement for the benefit of Cardinal Health to eliminate the uncertainty, distraction, disruption, burden, risk, and expense of further litigation. Pursuant to the terms set forth below, the Stipulation (including the exhibits thereto) shall in no event be construed as, or deemed to be evidence of, an admission or concession by the Defendants with respect to any claim of fault, liability, wrongdoing, or damage or any defect in the defenses that Individual Defendants have, or could have, asserted.
What claims will the Settlement release?

As part of the Settlement, the Parties agreed to give up certain rights called releases. If the Court approves the Settlement, the Court will enter a Judgment dismissing the Action with prejudice pursuant to the terms of the Stipulation and the following releases will occur:

Release of Claims by Plaintiffs, the Company, and the Company’s stockholders: Without further action by anyone, upon the Effective Date,5 Cardinal Health acting directly, Plaintiffs acting directly on behalf of themselves and derivatively on behalf of Cardinal Health, and any other Cardinal Health stockholder acting derivatively on behalf of Cardinal Health, and any of their respective legal representatives, heirs, executors, administrators, predecessors, successors, predecessors-in-interest, successors-in-interest and assigns, shall be deemed to have, and by operation of the Judgment, shall have, fully, finally, and forever released, relinquished, settled, discharged, and dismissed with prejudice every one of the Released Plaintiff Claims (including Unknown Claims) against the Released Defendant Persons, and shall be forever barred and enjoined from asserting, commencing, instituting, prosecuting, or continuing to prosecute any of the Released Plaintiff Claims against any of the Released Defendant Persons.

Release of Claims by Defendants: Without further action by anyone, upon the Effective Date, each of the Individual Defendants and Cardinal Health, and their respective legal representatives, heirs, executors, administrators, predecessors, successors, predecessors-in-interest, successors-in-interest and assigns, shall be deemed to have, and by operation of the Judgment, shall have, fully, finally, and forever released, relinquished, settled, discharged, and dismissed with prejudice every one of the Released Defendant Claims (including Unknown Claims) against the Released Plaintiffs, and shall be forever barred and enjoined from asserting any Released Defendant Claims against any of the Released Plaintiffs.
Nothing in the Judgment shall in any way impair or restrict the rights of any Party to enforce the terms of the Stipulation, the Settlement, or the Judgment.

THE ABOVE DESCRIPTION OF THE PROPOSED RELEASES IS A SUMMARY. The complete terms, including the definitions of the Effective Date, Released Plaintiff Claims, Released Defendant Persons, Unknown Claims, Released Defendant Claims,
5 The Effective Date of the Settlement is conditioned on the occurrence of each of the events described in Section 5.1 of the Stipulation, which include: (i) approval of the Settlement at or after the Settlement Hearing following notice to Current Company Stockholders as set forth in Section 3.2 of the Stipulation; (ii) entry of the Judgment dismissing the Action with prejudice pursuant to the terms of the Stipulation and releasing the Released Defendant Persons and the Released Plaintiffs from the Released Claims; and (iii) the passing of the date upon which the Judgment, including dismissal of the Action with prejudice pursuant to the terms of the Stipulation, becomes Final. “Released Claims” means, collectively, the “Released Defendant Claims” and the “Released Plaintiff Claims.”



Released Plaintiffs, and Released Persons, are set forth in the Stipulation, which is available on Cardinal Health’s investor relations website at ir.cardinalhealth.com and on Co-Lead Counsel’s websites at www.gardylaw.com and www.ktmc.com.

How will the attorneys be paid?

After the Parties had agreed on all other material terms of the Settlement, the Parties separately negotiated in good faith to attempt to reach agreement concerning the amount of the Fee and Expense Award for Plaintiffs’ Counsel.

Cardinal Health has agreed that Plaintiffs’ Counsel are entitled to receive 25% of the $124 million Settlement amount, subject to the approval of the Court, for their role in prosecuting and settling the Action. Plaintiffs’ Counsel have been working exclusively on a contingent fee basis, meaning that they would only be compensated for their time litigating the Action if they achieved a benefit for Cardinal Health through the Action. The Court may award less than the requested amount and any change to the negotiated amount of the Fee and Expense Award will not otherwise affect the Finality of the Settlement. The Court’s decision granting, in whole or in part, the application by Plaintiffs’ Counsel for a Fee and Expense Award is not a condition of the Settlement or to entry of the Judgment. The Parties acknowledge and agree that any Fee and Expense Award awarded by the Court in connection with the Settlement shall be paid by Defendants’ D&O Insurers to Plaintiffs’ Counsel and shall reduce the net Settlement amount paid to Cardinal Health. Cardinal Health stockholders are not personally liable for any such fees or expenses.

As part of Plaintiffs’ Counsel’s application for the Fee and Expense Award, Plaintiffs will also submit an application to the Court requesting service awards of $2,500 to each individual Plaintiff for their time and effort in prosecuting the Action. If approved, these service awards will be paid solely from the Fee and Expense Award.

When and where will the Court decide whether to approve the Settlement?

The Court will hold the Settlement Hearing at 2:00 p.m. on October 4, 2022, at the Joseph P. Kinneary U.S. Courthouse, Room 167, 85 Marconi Boulevard, Columbus, Ohio 43215. In light of the ongoing Covid-19 pandemic, the Court reserves the right (in the Court’s discretion) to hold the Settlement Hearing by telephone or videoconference, and will provide notice of such decision by way of docket entry.

At the Settlement Hearing, the Court will consider whether the Judgment, substantially in the form of Exhibit B to the Stipulation, should be entered: (i) approving the terms and conditions of the Settlement as fair, reasonable, and adequate and in the best interests of Cardinal Health and its stockholders, (ii) dismissing the Action with prejudice pursuant to the terms of the Stipulation, (iii) ruling on the application by Plaintiffs’ Counsel for the Fee and Expense Award, and (iv) ruling on Plaintiffs’ application for service awards. If there are objections, the Court will consider them. At or after the Settlement Hearing, the Court will make decisions whether to approve these matters relating to the Settlement. We do not know how long these decisions will take.

Please note that the date and time of the Settlement Hearing may change without further written notice to Current Company Stockholders. The Court further reserves the right to adjourn the Settlement Hearing, or any adjournment thereof, including the consideration of the application for the Fee and Expense Award and service awards, without further notice of any kind to Current Company Stockholders other than an announcement at the Settlement Hearing or at any adjournment of the Settlement Hearing. The Court reserves the right to approve the Settlement, at or after the Settlement Hearing, with such modifications as the Parties may agree to without further notice to Current Company Stockholders. The Court reserves its right to enter its Judgment approving the Settlement and dismissing with prejudice the claims asserted in the Action regardless of whether the Court has awarded the Fee and Expense Award and service awards. The Court also reserves the right to extend any of the deadlines set forth in the Preliminary Approval Order without further notice to Current Company Stockholders.

How do I tell the Court if I don’t like the Settlement?

If you were a stockholder of Cardinal Health as of the close of trading on the date of the Stipulation (May 25, 2022) and you continue to own such stock through the date of the Settlement Hearing, you can object to the Settlement, including Plaintiffs’ Counsel’s application for the Fee and Expense Award and service awards as described above. You can give reasons why you think the Court should not approve the Settlement, the Fee and Expense Award, the service awards, or any part thereof. The Court will consider your views.




To object, you must, no later than twenty-one (21) calendar days prior to the date of the Settlement Hearing (by September 13, 2022), file with the Court a written statement of your objection. Any such objection must also be received by the below-noted counsel by no later than twenty-one (21) calendar days prior to the date of the Settlement Hearing (by September 13, 2022). Your objection must clearly identify the case name and action number, In re Cardinal Health, Inc. Derivative Litigation, Case No. 2:19-cv-2491, and must: (i) state the name, address, and telephone number of the objector; (ii) be signed by the objector (or his, her, or its counsel); (iii) state whether the objector is represented by counsel and, if so, the name, address, and telephone number of his, her, or its counsel; (iv) contain a specific, written statement of the objection(s) and the specific reason(s) for the objection(s) or the reasons for the objector’s desiring to appear and be heard, including any legal and evidentiary support the objector wishes to bring to the Court’s attention; (v) include documentation sufficient to prove that the objector owned shares of Cardinal Health common stock as of the close of trading on May 25, 2022 and continues to own such shares; and (vi) state whether the objector and/or his, her, or its counsel intends to appear at the Settlement Hearing and identify any witnesses the objector may call to testify and any exhibits the objector intends to introduce into evidence at the Settlement Hearing. You do not need to hire an attorney. If you choose to hire an attorney, it is at your expense.

To file with the Court, you must either have an electronic filing account with United States District Court for the Southern District of Ohio through PACER (Public Access to Court Electronic Records) to file electronically or mail or hand-deliver your papers such that they are received no later than September 13, 2022 by the Office of the Clerk of the Court, United States District Court for the Southern District of Ohio, Eastern Division, Joseph P. Kinneary U.S. Courthouse, Room 121, 85 Marconi Boulevard, Columbus, Ohio 43215.

Hand-delivered filings can be made to any other location of the United States District Court for the Southern District of Ohio.

All objections must also be copied to the following attorneys:
Justin O. Reliford
Kessler Topaz Meltzer & Check, LLP
280 King of Prussia Road
Radnor, PA 19087
Email: jreliford@ktmc.com
Jennifer Sarnelli
Gardy & Notis, LLP
126 East 56th Street, 8th Floor
New York, NY 10022
Email: jsarnelli@gardylaw.com

Robert W. Trafford
Porter Wright Morris & Arthur LLP
41 South High Street
Suites 2800 - 3200
Columbus, OH 43215
rtrafford@porterwright.com

William Savitt
Wachtell, Lipton, Rosen & Katz
51 West 52nd Street
New York, NY 10019
WDSavitt@wlrk.com

Albert G. Lin
Baker Hostetler
200 Civic Center Drive, Suite 1200
Columbus, OH 43215
alin@bakerlaw.com

If you do not make your objection in the manner provided herein, you waive your right to object to the approval of the Settlement, the Judgment to be entered approving the Settlement, the application for a Fee and Expense Award, and the application for service awards (including any right of appeal or collateral attack), and shall be forever barred and foreclosed from objecting to the fairness, reasonableness, or adequacy of the Settlement, the Judgment to be entered approving the Settlement, the Fee and Expense Award, or the service awards, or from otherwise being heard concerning these matters in this or any other proceeding, and you will be bound by the Judgment approving the Settlement, including the Releases.

Do I have to come to the Settlement Hearing?

No. Plaintiffs’ Counsel will answer questions the Court may have, but you and/or your lawyer are welcome to come at your own expense. If you submit an objection, you do not have to come to Court to talk about it. As long as you filed and served your written objection with the proper documentation and in the manner described above and on time, the Court will consider it.



Unless the Court orders otherwise, any person who fails to object in the manner described above shall be deemed to have waived and forfeited any and all rights they may otherwise have to object to the Settlement and/or Plaintiffs’ Counsel’s application for the Fee and Expense Award and service awards (including any right of appeal) and shall be forever barred from raising such objection in the Action or any other action or proceeding. Cardinal Health stockholders who do not object need not appear at the Settlement Hearing or take any other action to indicate their approval.

How do I get more information?

This Notice only summarizes the Settlement and is not a full description of the Action. For more detailed information about the Action, you are referred to the papers on file in the Action, which may be inspected during regular business hours of each business day at the Office of the Clerk, Joseph P. Kinneary U.S. Courthouse, Room 121, 85 Marconi Boulevard, Columbus, OH 43215. Copies of the Stipulation, the Amended Complaint, and other important case documents are also available on Co-Lead Counsel’s websites: www.gardlylaw.com and www.ktmc.com. You may also obtain more information by reviewing the Stipulation, which is also available on the Cardinal Health investor relations website at ir.cardinalhealth.com.

If you have questions regarding the Settlement, you may write or call Co-Lead Counsel:

Justin O. Reliford
Kessler Topaz Meltzer & Check, LLP
280 King of Prussia Road
Radnor, PA 19087
Telephone: 610-667-7706
Email: jreliford@ktmc.com
Jennifer Sarnelli Gardy & Notis, LLP
126 East 56th Street, 8th Floor
New York, NY 10022
Telephone: 212-905-0509
Email: jsarnelli@gardylaw.com

PLEASE DO NOT CALL OR WRITE THE COURT OR THE OFFICE OF THE CLERK WITH QUESTIONS REGARDING THIS NOTICE OR TO INQUIRE ABOUT THE SETTLEMENT.

Form and substance approved by Court Order Dated July 18, 2022.




EX-99.3 4 exhibit993-8xk.htm EX-99.3 Document
Exhibit 99.3


image.jpg


Summary Notice to Stockholders of Cardinal Health, Inc. of Proposed Settlement of Stockholder Derivative Action, Settlement Hearing, and Right to Appear

TO: ALL PERSONS AND ENTITIES THAT HELD CARDINAL HEALTH, INC. COMMON STOCK AS OF THE CLOSE OF TRADING ON MAY 25, 2022 AND THAT CONTINUE TO HOLD CARDINAL HEALTH COMMON STOCK AS OF THE CLOSE OF TRADING ON OCTOBER 4, 2022.

PLEASE READ THIS SUMMARY NOTICE CAREFULLY AND IN ITS ENTIRETY.

The Court authorized this Summary Notice. This Summary Notice relates to a proposed settlement (the “Settlement”) of a stockholder derivative action: In re Cardinal Health, Inc. Derivative Litig., Case No. 2:19-cv-2491 (S.D. Ohio) (the “Action”). If the Court approves the Settlement, you will be forever barred from contesting the fairness, adequacy, and reasonableness of the Settlement and from pursuing the Released Claims.

The terms and conditions of the Settlement are set out in a Stipulation and Agreement of Compromise, Settlement, and Release, dated May 25, 2022 (the “Stipulation”). All capitalized terms used in this Summary Notice that are not otherwise defined herein have the meanings provided in the Stipulation and/or Notice.

Subject to the terms and conditions of the Stipulation, the Settlement will provide Cardinal Health with a gross payment of $124 million, less any Fee and Expense Award awarded by the Court to Plaintiffs’ Counsel. A more detailed description of the Action and the Settlement are set forth in the Stipulation as well as the full Notice to Cardinal Health, Inc. Stockholders of Proposed Settlement of Stockholder Derivative Action, Settlement Hearing, and Right to Appear (the “Notice”), both of which are publicly available for review on Cardinal Health’s investor relations website at ir.cardinalhealth.com.

The Court will hold a Settlement Hearing at 2 p.m. on October 4, 2022, either in person at the Joseph P. Kinneary U.S. Courthouse, Room 167, 85 Marconi Boulevard, Columbus, Ohio 43215, or by telephone or video conference, to consider whether the Judgment, substantially in the form of Exhibit B to the Stipulation, should be entered: (i) approving the terms and conditions of the Settlement as fair, reasonable, and adequate and in the best interests of Cardinal Health and its stockholders, (ii) dismissing the Action with prejudice pursuant to the terms of the Stipulation, (iii) ruling on the application by Plaintiffs’ Counsel for the Fee and Expense Award, and (iv) ruling on Plaintiffs’ application for service awards.

If you owned Cardinal Health stock (NYSE: CAH) as of the close of trading on May 25, 2022 and continue to hold Cardinal Health common stock as of the date of the Settlement Hearing, you may object to the Settlement, including Plaintiffs’ Counsel’s application for the Fee and Expense Award and service awards and appear at the Settlement Hearing to show cause why the Settlement, Judgment, or the applications for a Fee and Expense Award and service awards should not be approved and entered. Any such objections must be filed with the Court and served on counsel for the Parties no later than September 13, 2022 in accordance with the instructions set forth in the Notice.

PLEASE NOTE: Because the Settlement involves the resolution of a stockholder derivative action, which was brought on behalf of and for the benefit of the Company, the benefits from the Settlement will go to Cardinal Health. Individual Cardinal Health stockholders will not receive any direct payment from the Settlement. Accordingly, there is no proof of claim form for stockholders to submit in connection with this Settlement.

Stockholders are not required to take any action in response to this Summary Notice.

Please visit the Investor Relations section of Cardinal Health’s website to read the full Notice and Stipulation for more information. You may also email questions to Plaintiffs’ Counsel: Justin Reliford at jreliford@ktmc.com or Jennifer Sarnelli at jsarnelli@gardylaw.com. PLEASE DO NOT CONTACT THE COURT WITH QUESTIONS.




By Order of the Court

Contacts
Media: Erich Timmerman, erich.timmerman@cardinalhealth.com and (614) 757-8231
Investors: Kevin Moran, kevin.moran@cardinalhealth.com and (614) 757-7942.

EX-101.SCH 5 cah-20220718.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 cah-20220718_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 7 cah-20220718_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 image.jpg begin 644 image.jpg MB5!.1PT*&@H -24A$4@ -X !," 8 "R0G_ 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover Page
Apr. 02, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jul. 18, 2022
Entity Registrant Name Cardinal Health, Inc.
Entity Incorporation, State or Country Code OH
Entity File Number 1-11373
Entity Tax Identification Number 31-0958666
Entity Address, Address Line One 7000 Cardinal Place
Entity Address, City or Town Dublin
Entity Address, State or Province OH
Entity Address, Postal Zip Code 43017
City Area Code 614
Local Phone Number 757-5000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares (without par value)
Trading Symbol CAH
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0000721371
Amendment Flag false

XML 10 cah-20220718_htm.xml IDEA: XBRL DOCUMENT 0000721371 2021-04-02 2021-04-02 0000721371 false 8-K 2022-07-18 Cardinal Health, Inc. OH 1-11373 31-0958666 7000 Cardinal Place Dublin OH 43017 614 757-5000 false false false false Common shares (without par value) CAH NYSE false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.cardinal.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports cah-20220718.htm cah-20220718.xsd cah-20220718_lab.xml cah-20220718_pre.xml exhibit991-8xk.htm exhibit992-8xk.htm exhibit993-8xk.htm http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cah-20220718.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "cah-20220718.htm" ] }, "labelLink": { "local": [ "cah-20220718_lab.xml" ] }, "presentationLink": { "local": [ "cah-20220718_pre.xml" ] }, "schema": { "local": [ "cah-20220718.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cah", "nsuri": "http://www.cardinal.com/20220718", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cah-20220718.htm", "contextRef": "i91ce4f2993c248e6a1a056da25338264_D20210402-20210402", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.cardinal.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cah-20220718.htm", "contextRef": "i91ce4f2993c248e6a1a056da25338264_D20210402-20210402", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0000721371-22-000049-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000721371-22-000049-xbrl.zip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end